Glycopeptide Antibiotic Compounds Targeting Resistant Bacteria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The emergence of antibiotic-resistant pathogens such as MRSA, VRE, and Acinetobacter baumannii poses a significant public health threat due to the limited effectiveness of existing glycopeptide antibiotics, necessitating the development of novel compounds that can inhibit the replication and function of these resistant bacteria.
Innovation Solution
A novel glycopeptide compound of formula (I) and its pharmaceutical compositions are developed, which involve glycosylating a compound with a glycosyltransferase, deacylating it with a deacylase, and acylating it with an acyltransferase in the presence of an acyl donor, specifically incorporating an N-acyl-Glc pharmacophore to enhance antimicrobial activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing glycopeptide antibiotics (teicoplanin, vancomycin) are used to treat severe Gram-positive infections, then cell-wall integrity disruption is achieved, but antibiotic-resistant pathogens (MRSA, VRE, VRSA, VISA) emerge and render these drugs ineffective
Solution Approach 1:
The patent modifies the chemical structure of glycopeptide antibiotics by changing parameters at specific positions: introducing N-acyl-Glc pharmacophore at the penultimate residue (position 6), modifying the D-Ala-D-Ala terminus to D-Ala-D-Lac or D-Ala-D-Ser, and adjusting the aglycone sequence. These parameter changes enable the drug to bind to modified lipid II precursors in resistant bacteria, restoring effectiveness against MRSA, VRE, VRSA, and VISA strains
Solution Approach 2:
The patent creates composite glycopeptide compounds combining multiple functional modules: the N-acyl-Glc pharmacophore at position 6, the modified pentapeptide branch (D-Ala-D-Lac or D-Ala-D-Ser), and the aglycone sequence. This composite structure allows simultaneous binding to resistant bacteria and disruption of cell-wall integrity, overcoming the limitations of single-component original glycopeptides
2Reliability
If the D-Ala-D-Ala terminus of lipid II is modified to D-Ala-D-Lac or D-Ala-D-Ser to confer vancomycin resistance, then pathogen resistance is achieved, but the emergence of resistant strains (VRE, VRSA, VISA) increases public health threat
Solution Approach 1:
The patent converts the harmful resistance mechanism (modification of D-Ala-D-Ala to D-Ala-D-Lac or D-Ala-D-Ser) into a benefit by designing glycopeptide compounds that specifically target these modified termini. The drug's modified structure allows it to bind with high affinity to the resistant lipid II precursors, turning the resistance trait into a vulnerable target for the new antibiotic
Solution Approach 2:
The patent performs preliminary action by pre-modifying the glycopeptide structure before use, incorporating the N-acyl-Glc pharmacophore and modified pentapeptide sequence that are specifically designed to recognize and bind to the resistant lipid II precursors. This pre-prepared drug structure is already optimized to counteract the resistance mechanism before the drug encounters the resistant pathogen
3Reliability
If glycopeptide antibiotics bind to D-Ala-D-Ala terminus of Lipid II to disrupt cell-wall integrity, then antimicrobial activity is achieved, but the binding specificity limits effectiveness against diverse and resistant pathogens
Solution Approach 1:
The patent achieves universality by designing a glycopeptide compound with multi-functional capabilities: the N-acyl-Glc pharmacophore at position 6 provides broad-spectrum binding, the modified pentapeptide branch (D-Ala-D-Lac or D-Ala-D-Ser) enables recognition of resistant lipid II precursors, and the aglycone sequence facilitates cell-wall disruption. This multi-functional structure allows the single compound to effectively target diverse pathogens including Gram-positive and Gram-negative bacteria, as well as resistant strains
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel compound demonstrates broad-spectrum antimicrobial activity, effectively killing both gram-positive and gram-negative bacteria, including resistant strains, by disrupting cell-wall integrity and membrane permeability, offering a potential solution to the growing antibiotic resistance crisis.
Implementation Method 1
glycosylating a compound with a glycosyltransferase
Implementation Method 2
deacylating it with a deacylase
Implementation Method 3
acylating it with an acyltransferase in the presence of an acyl donor
Implementation Method 4
binds specifically to the D-Ala-D-Ala terminus of the pentapeptide branch of Lipid II disrupting cell-wall integrity of pathogens
Implementation Method 5
disrupting cell-wall integrity and membrane permeability
Data Source
AI summary
A teicoplanin derivative useful for treating an infectious disease, having the structure of formula (I):or the pharmaceutically acceptable salt, solvate, stereoisomer, derivative or prodrug thereof. In an exemplary compound of formula (I), R1 isR2 is H, R3 is —N(CH3)2, and R4 is H.